Ten-year fracture risk in the assessment of osteoporosis management efficacy in postmenopausal women: a pilot study

被引:3
|
作者
Pluskiewicz, W. [1 ]
Drozdzowska, B. [2 ]
Adamczyk, P. [3 ]
机构
[1] Dept & Clin Internal Dis Diabetol & Nephrol, Metab Bone Dis Unit, PL-41800 Zabrze, Poland
[2] Med Univ Silesia, Dept Pathomorphol, Katowice, Poland
[3] Med Univ Silesia, Dept & Clin Pediat, Katowice, Poland
关键词
FALLS; FRACTURE PROBABILITY; LONGITUDINAL RETROSPECTIVE STUDY; MANAGEMENT; MEN;
D O I
10.3109/13697137.2011.646345
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background The aim of the reported longitudinal, retrospective pilot study was to establish changes in 10-year fracture risk in postmenopausal women with respect to applied fracture management. Methods A group of 191 postmenopausal women with a mean age of 68.76 +/- 6.72 years was divided into subgroups. The subgroups were made up of untreated patients (n = 41), patients treated with vitamin D plus calcium (n = 46), and patients treated with bisphosphonates, vitamin D and calcium (n = 104). Repeated densitometric measurements and clinical data were taken into consideration (both baseline and follow-up). Ten-year fracture risk was established, using FRAX (TM) and Garvan nomograms. The mean follow-up period was 2.01 +/- 1.87 years. Results Generally, the mean fracture probability increased in the studied women over the observation period. Patients on bisphosphonate therapy demonstrated the smallest increase in fracture probability. The probability rate for either any fractures or hip fractures decreased when the T-score increased. A diminished number of falls non-significantly decreased the probability for hip fractures and any fractures. Conclusion Ten-year fracture risk increased irrespective of applied management, while a decreased risk was observed only in women with improved bone status.
引用
收藏
页码:117 / 126
页数:10
相关论文
共 50 条
  • [1] Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women
    Emkey, RD
    Reid, I
    Mulloy, AL
    Correa-Rotter, R
    Favus, M
    Bone, H
    Gupta, J
    LaMotta, A
    Santora, AC
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S32 - S32
  • [2] Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women
    Emkey, RD
    Reid, I
    Mulloy, AL
    Correa-Rotter, R
    Favus, M
    Bone, H
    Gupta, J
    La Motta, A
    Santora, AC
    BONE, 2003, 32 (05) : S206 - S206
  • [3] Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women.
    Emkey, R
    Reid, I
    Mulloy, A
    Correa-Rotter, R
    Favus, M
    Bone, H
    Gupta, J
    LaMotta, A
    Santora, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S139 - S139
  • [4] Ten-year fracture risk by FRAX® of women with osteoporosis attending osteoporosis care in Hungary
    Pentek Marta
    Gulacsi Laszlo
    Toth Edit
    Baji Petra
    Brodszky Valentin
    Horvath Csaba
    ORVOSI HETILAP, 2016, 157 (04) : 146 - 153
  • [5] Ten-Year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis with Denosumab Treatment
    Ferrari, S.
    Butler, P. W.
    Kendler, D. L.
    Miller, Paul D.
    Roux, C.
    Wang, A. T.
    Wagman, Rachel B.
    Lewiecki, E. M.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [6] Ten-year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis With Denosumab Treatment.
    Ferrari, S.
    Butler, P.
    Kendler, D. L.
    Miller, P. D.
    Roux, C.
    Wang, A. T.
    Wagman, R. B.
    Lewiecki, E. M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S25 - S25
  • [7] Comparison between ten-year fracture risk assessment by the Norland Illuminatus system and WHO based ten-year fracture risk assessments
    Sanchez, T. V.
    Wang, J. M.
    Schwalengberg, T. W.
    Dudzek, C. A.
    Ekker, G. J.
    BONE, 2009, 44 : S81 - S81
  • [8] TEN-YEAR PROBABILITY OF FRAGILITY FRACTURES IN PERI AND POSTMENOPAUSAL SAUDI WOMEN ACCORDING TO WHO FRACTURE RISK ASSESSMENT TOOL (FRAX)
    Al Fayaa, A. E.
    Al Mujli, A. A.
    Al Thani, A. S.
    Al Shehri, M. D.
    Al Khateeb, A. S.
    Al Khalifah, M. K.
    Al Asfour, A. M.
    Al Shker, S.
    Shahi, U.
    Al Farhan, M. F.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S305 - S306
  • [9] TEN-YEAR CONTINUED NONVERTEBRAL FRACTURE (NVFX) REDUCTION IN POSTMENOPAUSAL OSTEOPOROSIS WITH DENOSUMAB (DMAB) TREATMENT
    Ferraris, S.
    Butler, P. W.
    Kendler, D. L.
    Miller, P. D.
    Roux, C.
    Wang, A. T.
    Wagman, R. B.
    Lewiecki, E. M.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S56 - S57
  • [10] Osteoporosis and fracture risk assessment: improving outcomes in postmenopausal women
    Perez, Mariana Ortega
    Pedro, Pedro Paulo de Alcantara
    Lyrio, Andre Marun
    Grizzo, Felipe Merchan Ferraz
    Loures, Marco Antonio A. da Rocha
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2023, 69